Obicetrapib (TA-8995, AMG-899, DEZ-001) is an inhibitor of Cholesteryl Ester Transfer Protein (CETP) that significantly reduces non-HDL cholesterol (non-HDL-C) and lipoprotein(a) levels while increasing high-density lipoprotein cholesterol (HDL-C). It also has the potential to reduce major adverse cardiovascular events.